"我们对本届进博会满怀期待，并始终以饱满热情与信心投身其中。 一方面，我们期待借助进博会 的聚势效应，与中国医疗健康事业同频共振。通过这一平台，我们可以更精准地捕捉本土医患的临床痛 点与未被满足的需求，加速引入更加符合中国诊疗场景的创新产品，让中国患者同步享受到全球领先的 医疗科技成果，为"健康中国 2030"贡献切实力量。另一方面，我们也期待以进博会为纽带，推动'中国 范式'的医疗创新走向世界。进博会的深层价值在于搭建起开放协作的桥梁，让本土创新力量与国际资 源更高效地对接。我们希望通过研发合作、商业推广等多元生态协作，推动更多贴合临床需求的创新方 案落地和服务本土患者，也助力'中国智造'优质成果走向更广阔的世界舞台，提升全球医疗健康领域的 协作效能。"波士顿科学表示。 资料显示，波士顿科学是全球领先的创新医疗科技公司，1979年成立于美国。46年来，波士顿科学 始终致力于为生命创新，每年研发投入占营收10%以上，目前共有10款产品或技术获得被誉为医药界诺 贝尔奖的"盖伦奖"或被提名，2016至2025年连续十年入选《财富》全球最受赞赏公司榜单。1997年，波 士顿科学正式进入中国市场，在华业务覆盖心脏、外 ...

Boston Scientific (BSX 4.21%), a leader in medical devices for cardiovascular and surgical markets, reported its second-quarter 2025 results on July 23, 2025. The company posted revenue and earnings well above Wall Street expectations for the period, with revenue of $5.06 billion topping analyst estimates of $4.89 billion. Adjusted (non-GAAP) earnings per share (EPS) landed at $0.75, also ahead of the projected $0.73. Both numbers exceeded the upper end of Boston Scientific's own guidance. Management charac ...

Key Takeaways BSX posted Q2 adjusted EPS of 75 cents, up 20.9% and above guidance and consensus estimates. Q2 revenues rose 22.8% to $5.06B, driven by 26.8% Cardiovascular growth and strong U.S. performance. BSX raised 2025 sales growth forecast to 18-19% and EPS guidance to $2.95-$2.99 on solid portfolio momentum.Boston Scientific Corporation (BSX) posted second-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 20.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 4 ...

Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

Core Insights - Boston Scientific Corporation reported net sales of $5.061 billion for Q2 2025, representing a growth of 22.8% on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis compared to the previous year [1][7][10] - The company achieved a GAAP net income of $797 million, or $0.53 per share, compared to $324 million, or $0.22 per share, a year ago, with adjusted EPS of $0.75 compared to $0.62 a year ago [1][7][10] Financial Performance - The second quarter financial results showed significant growth across various segments, with MedSurg growing by 15.7% reported, Cardiovascular by 26.8% reported, and Urology by 28.9% reported [6][7] - The net sales growth by region included a 30.7% increase in the U.S., 6.8% in EMEA, 18.0% in APAC, and 11.6% in Emerging Markets [7][8] Strategic Developments - The company received FDA approval to expand the use of the FARAPULSE™ Pulsed Field Ablation System for treating drug refractory, symptomatic persistent atrial fibrillation [7] - Boston Scientific commenced enrollment in the ReMATCH IDE clinical trial for evaluating the FARAWAVE™ and FARAPOINT™ PFA Catheters [7] - The company completed acquisitions of Intera Oncology® Inc. and SoniVie Ltd., enhancing its product offerings in the medical device sector [7] Guidance - For the full year 2025, Boston Scientific estimates net sales growth of approximately 18% to 19% on a reported basis and 14% to 15% on an organic basis [10][11] - The company projects GAAP EPS in the range of $1.89 to $1.93 and adjusted EPS of $2.95 to $2.99 for the full year [10][11]

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]

2025年2月5日， 波士顿科学 公布了 2024年第四季度及全年业绩 ， 第四季度销售额 45.61亿美元（约合332亿人民币） ，同比增长22.4%；全年总营收 167.47亿美元（约合1220亿人民币） ， 同比 增长17.6%。 # 财报亮点 第四季度的净销售额 为45.61亿美元 ，同比增长22.4%（报告）、23.1%（运营）和19.5%（有机）；每股收益（EPS）为0.38美元，同比增长11.8%，调整后 为0.70美元，同比增长27.3%； 毛利率为67.9%，同比下降130个基点；调整后为70.6%，同比增长20个基点；营业利润率为14.8%，同比下降90个基点；调整 后为27.4%，同比增长80个基点。 全年净销售额为167.47亿美元 ，同比增长17.6%（报告）、18.5%（运营）和16.4%（有机）；每股收益（EPS）为1.25美元，同比增长20.0%，调整后为2.51 美元，同比增长100.0%；毛利率为68.6%，同比下降90个基点；调整后为70.3%，同比下降40个基点；营业利润率为15.5%，同比下降100个基点，调整后为 27.0%，同比增长70个基点。 | Q4 & FY ...